NCT03019757 Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
| NCT ID | NCT03019757 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Douglas Scharre |
| Condition | Alzheimer's Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 76 participants |
| Start Date | 2018-08-30 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 76 participants in total. It began in 2018-08-30 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.
Eligibility Criteria
Inclusion Criteria: * Subjects must meet the standard clinical criteria of the syndromes of interest * All subjects must have enough cognitive abilities to complete study procedures, which will be operationally defined as having a Mini Mental State Examination (MMSE) score greater or equal to 10. * Subjects must be on stable cognitive and psychoactive medication regimen for the preceding four weeks of enrollment. * Subjects must have a responsible study partner that either lives with them or is in regular contact with them at least 4 out of 7 days per week. * Subjects must have visual and auditory acuity adequate for testing. Exclusion Criteria: * Any other condition (other than the primary diagnosis), which in the opinion of the investigators might contribute to the syndrome of dementia or complicate its assessment. * active medical disorder that could preclude participation in this protocol * Women who are pregnant or are breast feeding * severe renal impairment as defined by glomerular filtration rate (GFR) less than 30 (may have increased radiation exposure with the DaTscan). * Subjects in whom English is not the 1st language * Subjects with educational level less than 12 years * Subjects who have ever participated in an experimental study with an amyloid targeting agent unless it can be documented that the subject received only placebo during the course of the trial.
Contact & Investigator
Douglas W Scharre, MD
PRINCIPAL INVESTIGATOR
Ohio State University
Frequently Asked Questions
Who can join the NCT03019757 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alzheimer's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03019757 currently recruiting?
Yes, NCT03019757 is actively recruiting participants. Contact the research team at jennifer.icenhour@osumc.edu for enrollment information.
Where is the NCT03019757 trial being conducted?
This trial is being conducted at Columbus, United States.
Who is sponsoring the NCT03019757 clinical trial?
NCT03019757 is sponsored by Douglas Scharre. The principal investigator is Douglas W Scharre, MD at Ohio State University. The trial plans to enroll 76 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.